As announced on 4 March 2025, Spermosens secured a strategic investment of SEK 10.8 million through a directed issue to investors from Germany, Scandinavia and the United States. The investment strengthens the Company’s financial position, enabling it to accelerate development and advance ongoing business development efforts. With a clear strategy to secure licensing agreements, Spermosens is now well-positioned to establish JUNO-Checked in the ART market.

The ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö has already shown promising interim results, demonstrating a positive correlation between JUNO binding, the sperm cell’s ability to attach to the egg, and improved fertilization and pregnancy outcomes. The study is expected to continue generating clinical evidence, validating the diagnostic relevance of Spermosens’ patented technology. The Company aims to present interim results quarterly, with the ambition to finalize the study in 2025. Upon completion of the clinical study and optimization of the JUNO-Checked technology, Spermosens will work to secure licensing agreements, including upfront payments, milestones and future royalties on net sales.

In parallel with the clinical study, Spermosens will refine its JUNO-Checked system and technology through two key initiatives to make the technology commercially viable and attractive for partners:

1. Product customization and system integration
   The Company, in collaboration with FlexMedical Solutions and PalmSens, plans to customize and integrate the system with commercially available instruments.
2. Technology maturation
   The Company aims to improve the accuracy, efficiency and performance of JUNO-Checked to reduce assay complexity and time, enhancing commercial viability. The technology optimization may also expand Spermosens' intellectual property portfolio.

Spermosens is already in discussions with potential partners in several key markets and is experiencing growing interest in its unique technology. By completing these key initiatives, Spermosens is preparing to engage more closely with potential partners in Europe, the United States, Japan and Korea. The goal is to secure license agreements that will unlock revenue potential, positioning the Company to achieve positive cash flow from the second half of 2026.

The recent strategic investment has laid the foundation for these initiatives, and the Company remains focused on executing its plan to deliver innovative diagnostic solutions addressing the global infertility challenges.

Tore Duvold, CEO of Spermosens, comments: "The recent investment marks an important turning point for Spermosens and we are pleased to reveal our plan to become cash positive. We are now in a good position to complete the final stages of developing our unique JUNO-Checked technology, which holds the potential to significantly improve fertility diagnostics and treatment. With our clinical study progressing well and showing promising early results, we are focused on optimizing the technology and positioning the company for success in the large and growing ART market. Our strategy is clear: leverage our innovation to form partnerships that will bring our solution to global markets, from Europe to Japan and the US. This investment is not just a financial boost; it is a key enabler in accelerating our development, securing strategic partnerships and ultimately helping the many couples struggling with infertility."

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checkedproduct aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com